<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2014399</article-id><article-id pub-id-type="pmcid-ver">PMC2014399.1</article-id><article-id pub-id-type="pmcaid">2014399</article-id><article-id pub-id-type="pmcaiid">2014399</article-id><article-id pub-id-type="pmid">10930972</article-id><article-id pub-id-type="doi">10.1111/j.1365-2125.2000.00179.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Republication</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion <italic toggle="yes">vs</italic> intermittent bolus injection in septicaemic melioidosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Angus</surname><given-names initials="BJ">B J</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="MD">M D</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref><xref ref-type="author-notes" rid="fn1">&#8225;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suputtamongkol</surname><given-names initials="Y">Y</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mattie</surname><given-names initials="H">H</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walsh</surname><given-names initials="AL">A L</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref><xref ref-type="author-notes" rid="fn2">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wuthiekanun</surname><given-names initials="V">V</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chaowagul</surname><given-names initials="W">W</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>White</surname><given-names initials="NJ">N J</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><aff id="au1"><label>1</label><institution>Faculty of Tropical Medicine, Mahidol University</institution><addr-line>420/6 Rajvithi Road, Bangkok 10400, Thailand</addr-line></aff><aff id="au2"><label>2</label><institution>Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford University</institution><addr-line>Oxford, United Kingdom</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Infectious Diseases, University Hospital</institution><addr-line>Leiden, The Netherlands</addr-line></aff><aff id="au4"><label>4</label><institution>Department of Medicine, Sappasitprasong Hospital</institution><addr-line>Ubon Ratchatani, Thailand</addr-line></aff><aff id="au5"><label>5</label><institution>Department of Medicine, Siriraj Hospital</institution><addr-line>Bangkok, Thailand</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic toggle="yes">Correspondence:</italic> Professor N.J. White, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand. Tel.: 662&#8211;246&#8211;0832; Fax: 662&#8211;246&#8211;7795; E-mail: <email>fnnjw@diamond.mahidol.ac.th</email></corresp><fn id="fn1"><label>&#8225;</label><p>Current addresses: Public Health Laboratory, Taunton &amp; Somerset Hospital, Taunton, United Kingdom.</p></fn><fn id="fn2"><label>&#8224;</label><p>Wellcome Unit, Queen Elizabeth Hospital, Blantyre, Malawi.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2000</year></pub-date><volume>50</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">151551</issue-id><fpage>184</fpage><lpage>191</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2001</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2015-10-26 22:24:56.210"><day>26</day><month>10</month><year>2015</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0050-0184.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="republished-article" xml:lang="en" xlink:title="research-article" vol="49" page="445" journal-id="Br J Clin Pharmacol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC2014958"><article-title>Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion <italic>vs</italic> intermittent bolus injection in septicaemic melioidosis</article-title><volume>49</volume><issue>5</issue><date><month>5</month><year>2000</year></date><fpage>445</fpage><lpage>452</lpage><source>British Journal of Clinical Pharmacology</source><pub-id pub-id-type="pmcid">PMC2014958</pub-id><pub-id pub-id-type="pmid">10792202</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="repub-note" xml:lang="en" xlink:title="correction" vol="50" page="183" journal-id="Br J Clin Pharmacol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC2064972"><article-title>Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion <italic>vs</italic> intermittent bolus injection in septicaemic melioidosis</article-title><volume>50</volume><issue>2</issue><date><month>8</month><year>2000</year></date><fpage>183</fpage><lpage>183</lpage><source>British Journal of Clinical Pharmacology</source><pub-id pub-id-type="pmcid">PMC2064972</pub-id></related-article><abstract><sec><title>Aims</title><p>Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta-lactam antibiotics for serious Gram-negative infections. Severe melioidosis (<italic toggle="yes">Burkholderia pseudomallei</italic> infection) carries a mortality over 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime <italic toggle="yes">vs</italic> intermittent bolus dosing in septicaemic melioidosis.</p></sec><sec><title>Methods</title><p>Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg<sup>&#8722;1</sup> 8 hourly by bolus injection or 4 mg kg<sup>&#8722;1</sup> h<sup>&#8722;1</sup> by constant infusion following a 12 mg kg<sup>&#8722;1</sup> priming dose and pharmacokinetic and pharmacodynamic parameters were compared.</p></sec><sec><title>Results</title><p>Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for <italic toggle="yes">B. pseudomallei</italic> of whom 12 (60%) died. The median MIC<sub>90</sub> of <italic toggle="yes">B. pseudomallei</italic> was 2 mg l<sup>&#8722;1</sup>, giving a minimum target concentration (4*MIC) of 8 mg l<sup>&#8722;1</sup>. The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half-lives of ceftazidime were 0.468 (0.241&#8211;0.573) l kg<sup>&#8722;1</sup>, 0.058 (0.005&#8211;0.159) l kg<sup>&#8722;1</sup> h<sup>&#8722;1</sup> and 7.74 (1.95&#8211;44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (<italic toggle="yes">r</italic> = 0.71; <italic toggle="yes">P</italic> &lt; 0.001) and there was no evidence of significant nonrenal clearance.</p></sec><sec><title>Conclusions</title><p>Simulations based on these data and the ceftazidime sensitivity of the <italic toggle="yes">B. pseudomallei</italic> isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure, which is common in patients with meliodosis is Clearance = <italic toggle="yes">k</italic> * creatinine clearance where <italic toggle="yes">k</italic> = 0.72. Calculation of a loading dose gives median (range) values of loading dose, <italic toggle="yes">D</italic><sub>L</sub> of 18.7 mg kg<sup>&#8722;1</sup> (9.5&#8211;23) and infusion rate I = 3.5 mg kg<sup>&#8722;1</sup> h<sup>&#8722;1</sup> (0.4&#8211;13) (which equals 84 mg kg<sup>&#8722;1</sup> day<sup>&#8722;1</sup>). A nomogram for adjustment in renal failure is given.</p></sec></abstract><kwd-group><kwd><italic toggle="yes">Burkholderia pseudomallei</italic></kwd><kwd>ceftazidime</kwd><kwd>continuous infusion</kwd><kwd>melioidosis therapy</kwd><kwd>pharmacodynamics</kwd><kwd>pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>